Rare Diseases Need Ongoing Natural History Studies To Speed Trials, FDA Says
By
Derrick Gingery / Email the Author / “The Pink Sheet” Nov. 14, 2011, Vol. 73, No. 46
Regulatory Update / Word Count: 835 / Article # 00111114003
Executive Summary
CDER Director Janet Woodcock says rare disease advocates should consider organizing patients to study a rare disease history and progression.
Already a Subscriber?
Log in for complete access.
Log In
Questions?
Call Toll-Free (800) 332-2181 or +1 (908) 547-2159.